Mapping ultrasound transducers

Information

  • Patent Grant
  • 8661873
  • Patent Number
    8,661,873
  • Date Filed
    Thursday, October 14, 2010
    13 years ago
  • Date Issued
    Tuesday, March 4, 2014
    10 years ago
Abstract
Ultrasound transducers may be mapped by varying a focus-affecting parameter and adjusting the parameter so as to improve focus quality. In some embodiments, mapping involves successively varying the phase of one transducer element, or group of elements, with respect to a constant phase of the other transducer elements, and determining the phase at which a tissue displacement in the ultrasound focus is maximized.
Description
FIELD OF THE INVENTION

The present invention relates, generally, to systems and methods for mapping ultrasound transducers. In particular, various embodiments are directed to improving the quality of the ultrasound focus using experimental feedback.


BACKGROUND

Focused ultrasound (i.e., acoustic waves having a frequency greater than about 20 kilohertz) can be used to image or therapeutically treat internal body tissues within a patient. For example, ultrasonic waves may be used to ablate tumors, eliminating the need for the patient to undergo invasive surgery. For this purpose, a piezo-ceramic transducer is placed externally to the patient, but in close proximity to the tissue to be ablated (“the target”). The transducer converts an electronic drive signal into mechanical vibrations, resulting in the emission of acoustic waves. The transducer may be shaped so that the waves converge in a focal zone. Alternatively or additionally, the transducer may be formed of a plurality of individually driven transducer elements whose phases can each be controlled independently from one another. Such a “phased-array” transducer facilitates steering the focal zone to different locations by adjusting the relative phases between the transducers. Magnetic resonance imaging (MRI) may be used to visualize the patient and target, and thereby to guide the ultrasound beam.


The effectiveness of ultrasound therapy depends on the accuracy of the focus location, the sharpness and shape of the focal zone, and the avoidance of “hot spots” (i.e., regions of high ultrasound intensity) outside the target. Transducer elements that are not properly configured or controlled can lead to improper focus location and reduced focus quality, resulting in less effective therapy, and possibly damage to healthy tissue surrounding the target. It is therefore desirable to correct any mechanical misconfigurations. Improper transducer configuration may result from manufacturing errors, inadvertent shifting of transducer elements from their expected locations during use or repair, deformation of the transducer due to thermal expansion, or a combination of these and other effects. Even slight locational deviations can have significant effects on the quality of the transducer output. For example, as illustrated in FIG. 1, if the height of a curved transducer surface having a width of 120 mm and a nominal radius of curvature of 160 mm changes by only 1 mm, the ultrasound focus shifts by about 13 mm. In a phased array, deviations of the transducer locations from the intended locations can be compensated for by adjusting the phases with which the elements are driven. This procedure is hereinafter referred to as “mapping” the transducer.


One approach to mapping a phased-array transducer surface involves driving each transducer element individually to produce an acoustic wave pulse in water; measuring the arrival of the acoustic wave pulse in three locations using a hydrophone; determining for each location the time of flight, and thus the distance, from the transducer element; and calculating the coordinates of the element location by triangulation from the three measurements. Based on the intended and the measured actual locations of the transducer elements, the necessary phase adjustments can be calculated. This method is described in U.S. Pat. No. 7,535,794 to Prus et al., which is hereby incorporated herein by reference in its entirety. In addition to a hydrophone, implementation of the method requires other auxiliary equipment, such as an amplifier and data-acquisition module. Further, to avoid damaging the hydrophone, the mapping is typically performed at transducer power levels significantly below those used during normal operation, which can undermine the validity of the adjustments under therapeutic conditions. Alternative transducer mapping methods that do not have these drawbacks are therefore desirable.


SUMMARY

The present invention generally provides methods for mapping a phased-array transducer by generating an ultrasound focus and improving the focus quality based on experimental feedback. In various embodiments, one or more focus-affecting parameters (such as the phase and/or amplitude of one or more transducer elements) are varied, and the resulting variation of the focus quality is measured (e.g., in terms of an integral or peak intensity, focus size, or intensity profile). The focus-affecting parameter(s) are then set to values for which the focus quality is optimized. For example, the relative phases of the transducer elements may be fine-tuned one at a time to maximize the intensity at the focus. In this manner, unwanted phase shifts resulting from electronic delays or other sources may be corrected, and any deviations from the intended locations of the transducer elements may be compensated for without the need to explicitly determine the actual transducer locations.


During the mapping procedure, the ultrasound focus may be generated in a phantom. To determine the focus quality, the focus may be visualized, for example, by magnetic-resonance acoustic radiation force imaging (MR-ARFI)—an MRI technique measuring minute material displacements that are caused by and indicative of the acoustic field. The displacement increases with the acoustic field intensity. Thus, by adjusting the transducer element phases (and/or amplitudes or other focus-affecting parameters) so as to increase the material displacement in the phantom, the intensity at the focus and, consequently, the focus quality may be improved. Advantageously, MR-ARFI facilitates mapping the transducer at normal operational power levels, which increases the relevance and applicability of any mapping-based adjustments to the subsequent therapeutic operation. Further, the ultrasound focus may be imaged during the mapping procedure with the same MRI or other imaging apparatus (e.g., X-ray-based computer-aided tomography or other tomographic modality) that is used to guide the focus during therapeutic operation, and, consequently, additional (auxiliary) mapping equipment is not needed.


In one aspect, the invention provides a method for improving and/or optimizing the focus of an ultrasound transducer having a plurality of transducer elements. The method includes driving the plurality of transducer elements so as to generate an ultrasound focus, varying a focus-affecting parameter associated with one or more of the transducer elements, measuring a resulting variation on the quality of the focus, and selecting parameter value(s) that result in the best focus quality. The focus-varying parameter(s) may be or include the phase and/or amplitude of one of the transducer elements (or a group of jointly driven elements), or a phase/amplitude gradient or other parameter determining relative phase/amplitude settings of multiple transducer elements that form the whole transducer or a region thereof, or a combination of such parameters. In embodiments in which the location and/or orientation of the transducer or transducer elements are susceptible to direct user control, the focus-varying parameter(s) may, alternatively or additionally, include such location(s) and/or orientation(s). Other focus-varying parameters include, e.g., the drive frequency of the transducer. The quality measurement may involve, for instance, scanning a profile of the focus (e.g., measuring the intensity in the focus region along a line through the focus), measuring the peak (i.e., maximum) intensity of the focus, and/or measuring the integral intensity or size of the focus (i.e., integrating the intensity or area over the cross-section of the focus, where the cross-section is defined, e.g., by the regions in which the intensity is more than a set fraction, e.g., half or 1/e, of the peak intensity).


In certain embodiments, varying the focus-varying parameter(s) and measuring the resultant focus quality includes driving a selected one of the transducer elements at a variable phase while driving the other transducer elements at a constant phase (thereby varying the focus quality); determining the phase difference, if any, between the constant and variable phases where the focus quality is optimized; and, if the phase difference is non-zero, adjusting the relative phase of the selected transducer element based thereon. These steps may be repeated for the remaining transducer elements.


In some embodiments, the quality measurement comprises measuring the displacement associated with the focus using, e.g., ARFI. The ARFI measurement may involve applying a sequence of MR field gradients (such as, e.g., repeated bipolar gradients). The ultrasound focus may generated by an ultrasound pulse synchronized with the sequence of MR field gradients. The method may further involve providing a phantom (which may include a material having low tensile strength and/or a small elastic modulus), and generating the ultrasound focus and measuring the focus quality in the phantom.


In another aspect, the invention is directed to a method for mapping an ultrasound transducer comprising a plurality of transducer elements. The method includes driving the transducer elements so as to generate an ultrasound focus, and measuring a displacement associated with the focus by ARFI. Further, it involves varying the displacement by driving one of the transducer elements at a variable phase while driving the other transducer elements at a constant phase, and determining the phase difference, if any, between the constant and variable phases at which the displacement is maximized. If the phase difference is non-zero, the relative phase of the selected transducer element is adjusted based on the phase difference. The phase difference may also be used to determine the location of the selected transducer element. The application of a variable phase and determination of the phase difference between the variable and constant phases may be repeated for the remaining transducer elements. The ultrasound focus may be generated, and the displacement be measured, in a phantom, which may have a low tensile strength and/or a small elastic modulus. Acoustic-radiation force imaging to measure the displacement may involve applying a sequence of MR field gradients, e.g., a sequence including repeated bipolar gradients. The transducer elements may be driven so as to generate an ultrasound pulse synchronized with the sequence of MR field gradients.


The above-described mapping method(s) may be varied by grouping transducer elements and mapping a group, rather than an individual element, at a time. Accordingly, in yet another aspect of the invention, a selected group of transducer elements is driven at a variable phase while other groups of transducer elements are driven at a constant phase, and the phase difference between the constant and variable phases that maximizes the displacement associated with the focus may be determined and form the basis for adjusting the relative phase of the selected group of transducer elements.


In a further aspect, the invention is directed to a method for controlling an ultrasound transducer having a plurality of transducer elements. The method includes mapping the ultrasound transducer as described above by driving the transducers to generate an ultrasound focus; varying a focus-affecting parameter associated with at least one of the elements and measuring a resulting variation on a quality of the focus; and selecting a value of the parameter associated with a best focus quality. In particular, in some embodiments, mapping may include measuring a displacement associated with the focus (e.g., using ARFI), and determining, for each of the transducer elements, the relative phase associated with that element by driving the transducer element at a variable phase while driving the other transducer elements at a constant phase and determining the phase difference between the constant and variable phases that maximizes the displacement. The method further includes controlling the transducer based on the mapping step (e.g., by adjusting the relative phase of each transducer for which the phase difference is non-zero). Controlling the transducer may include driving the elements to produce outputs converging at a focus corresponding to a target treatment region. Mapping may be carried out using a phantom, and may be repeated in between therapeutic applications of ultrasound.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing will be more readily understood from the following detailed description of the invention in conjunction with the drawings, wherein:



FIG. 1 is a schematic drawing illustrating the effect of a change in the transducer surface on the focus location;



FIG. 2 is a block-diagram illustrating, on a high level, a system for performing transducer mapping in accordance with some embodiments of the invention;



FIG. 3 a schematic diagram illustrating, in more detail, the configuration of a transducer mapping system in accordance with some embodiments;



FIGS. 4A-4C illustrate various MR-ARFI sequences in accordance with some embodiments;



FIG. 5 is an image of material displacements in an ultrasound focus region in accordance with some embodiments;



FIG. 6 is a graph illustrating material displacement in the focus center as a function of the phase of an individual transducer element, as it may be used in mapping methods in accordance with various embodiments; and



FIG. 7 is a flow chart illustrating an approach to mapping an ultrasound transducer array in accordance with various embodiments of the invention.





DETAILED DESCRIPTION


FIG. 2 illustrates in block-diagram form an exemplary system for performing transducer mapping in accordance with various embodiments hereof, and the interplay between the different system components. The system includes, first, the focused ultrasound transducer hardware 202, which itself includes the transducer array, a frequency generator for providing an electronic drive signal, and drivers for the transducer elements. (As used herein, the term “transducer” refers to the entire array, as distinguished from the individual transducer elements.) Each driver contains electronic circuitry for setting the phase of the respective transducer element(s), and optionally also for adjusting the amplitude(s) of vibrations. In some embodiments, each transducer elements is independently controllable by a separate associated driver. In alternative embodiments, driver elements are organized (e.g., via hardwiring or configurable switches) into multiple groups of elements driven collectively by the same driver. The drivers are controlled by a control station 204, which may include a computer system specially designed for use with the transducer hardware, or a general-purpose computer (or cluster of computers) having suitable (and conventional) driver software installed.


The mapping system 200 further includes MRI (or other tomographic or imaging) hardware 206, i.e., an MRI apparatus and related driver components, which is likewise controlled by the control station 204. Again, control functionality for the MRI hardware 206 may be implemented in a special-purpose computer system, or in conventional driver software installed on a general-purpose computer system. The transducer hardware 202 and MRI hardware 206 may be controlled by the same computer within control station 204, or by separate computers that are in communication with one another. Further, computational functionality for processing and analyzing the images acquired with the MRI hardware 206 may be integrated with the MRI apparatus, or implemented (e.g., as a separate software module) in control station 204.


During the mapping procedure, the control station 204 sends control signals to the ultrasound transducer hardware 202 to vary one or more parameters affecting the focus properties. For example, the control station 204 may cause a phase modulation of a particular transducer element or group of elements. Further, the control station 204 provides scan parameters, or other signals triggering and/or controlling image acquisition, to the MRI or other imaging hardware 206. The relative timing of the ultrasound generation and/or modulation with respect to image acquisition may be specified in an imaging sequence, which may be programmed into the control station 204. The control station 204 may then send trigger signals to the ultrasound transducer hardware 202 and the MRI hardware 206, ensuring correct timing between the signals in accordance with the imaging sequence. Alternatively, the control station 204 may communicate a time-delay parameter, which specifies the time delay between the RF pulses and ultrasound pulses, to the MRI hardware 206, which sends a corresponding trigger pulse directly to the ultrasound transducer hardware 204.


The acquired images are processed to determine one or more parameter(s) indicative of the focus quality, which are used in the control station 204 for subsequent mapping steps. For example, in MR-ARFI-based systems, a material displacement indicative of the intensity in the focus is computationally extracted from the images, and the transducer is iteratively adjusted so as to increase the material displacement. Similarly, if thermal MRI is employed, the mapping process involves maximizing the temperature, and thus intensity, in the focus. In general, any imaging technique that provides images suitable for determining focus quality may be used. Depending on the contemplated ultrasound application, the “quality” of the focus may be expressed by different parameters. For therapeutic applications involving targeted tissue destruction, for example, the focus quality may be measured in terms of a peak intensity or total power delivered (corresponding to an integrated intensity over the focus cross section). If the target area is small, the focus size may be relevant (a smaller focus area generally corresponding to higher focus quality). In some applications (e.g., tissue heating for palliative purposes), homogeneity of the intensity focus area may be important, and focus quality may, accordingly, be measured, at least in part, by the “smoothness” of an intensity profile through the focus.



FIG. 3 schematically illustrates an experimental setup for mapping an ultrasound transducer using tissue displacement as an indicator of focus quality. During the mapping procedure, the transducer 300 is driven so as to focus an ultrasound wave pulse into a phantom 302, which comprises or consists of a material that responds to acoustic pressure in a detectable manner. The ultrasound wave exerts acoustic radiation pressure onto the phantom material along its path. At the focus 304, where waves from the individual transducer elements converge, this pressure is highest, resulting in a temporary local displacement of the material in the longitudinal direction and/or in shear waves that propagate radially away from the focus. By using a soft phantom that responds to acoustic pressure with large enough shear strain (e.g., with a shear strain of at least 10−2), a detectable displacement field that directly reflects the acoustic field may be obtained. Suitable phantom materials have high tensile strength (e.g., higher than 100 kPa) and small elastic moduli (e.g., Young's modulus less than 1 MPa), and may include or consist of jelly-like materials such as, e.g., Silicone Gel RTV6166, provided by General Electric Co., Waterford, N.Y.


The material displacement may be visualized in an imaging plane 306 using an imaging techniques such as, e.g., magnetic-resonance-based acoustic radiation force imaging (MR-ARFI). In MR-based imaging methods, the object to be imaged (here, the phantom) is placed in a relatively uniform static magnetic field having a field strength of, typically, between about 1.5 and about 3.0 Tesla. Such a field may be generated, for example, by a large cylindrical electromagnet coil 308. The static magnetic field causes hydrogen nuclei spins to align and precess about the general direction of the magnetic field. Radio frequency (RF) pulses and magnetic gradients are then superimposed on the static magnetic field to cause some of the aligned spins to alternate between a temporary high-energy non-aligned state and the aligned state, thereby inducing an RF response signal, called the MR echo or MR response signal, in the RF antenna 310.


In MR-ARFI, transient-motion or displacement-sensitizing magnetic field gradients are applied to the phantom by gradient coils, which are part of standard MRI systems and are typically located near the cylindrical electromagnet coil 308. When the ultrasound pulse is applied in the presence of such gradients, the resulting displacement is directly encoded into the phase of the MR response signal. For example, the gradient coils and transducer may be configured such that the ultrasound pulse pushes phantom material near the focus towards regions of the magnetic field with higher field strengths. In response to the resulting change in the magnetic field, the phase of the MR response signal changes proportionally, thereby encoding in the signal the displacement caused by the ultrasound radiation pressure.


To achieve high image contrast, the ultrasound pulse, encoding gradients, and RF pulse are precisely timed with respect to each other according to a suitable displacement-encoding sequence. FIGS. 4A-4C illustrate five exemplary MR-ARFI sequences that may be used in embodiments of the invention. These sequence diagrams illustrate the order in which the displacement-encoding magnetic field gradients (thin solid lines), ultrasound pulses (dotted lines), and RF pulses (thick solid lines) appear in time. Three different field gradient sets are shown: two single lobes (a), repeated bipolars (b), and inverted bipolars (c). For gradient set (a), ultrasound may be applied during either the first or the second lobe. Similarly, for gradient set (c), ultrasound may be applied during the first or the second halves of the bipolars. In general, MR-ARFI sequences utilize magnetic field gradients that are synchronized with the ultrasound pulses. In preferred embodiments, a sequence like the repeated bipolar sequence (b) shown in FIGS. 4A-4C may be used.


An example of an MR-ARFI image of an ultrasound focus region is shown in FIG. 5. As shown, the material displacement with respect to an equilibrium position varies between about −1 μm and 5 μm, as indicated in the color-coding of the image. In general, the stronger the acoustic field intensity, the greater will be the maximum displacement at the center of the focus. The acoustic field intensity, in turn, is maximized when the elements of the ultrasound transducer emit acoustic waves that are all in phase at the focus position. If a transducer element is out of phase with respect to the others, the focus intensity in the center decreases. This relationship can be exploited to optimize the focus, and thus to map and adjust the transducer elements. Assuming, for example, that all but one of the transducer elements are properly configured, the correct phase of the last element can be determined by tuning the phase over a full cycle (e.g., between −π and +π), measuring for each phase the displacement in the focus center, and then setting the phase to the value corresponding to the maximum displacement. FIG. 6 depicts the results of such an adjustment procedure. In the illustrated example, the material displacement over the full phase cycle of one element varies between about 4.85 μm and about 5.4 μm. The maximum displacement occurs at about 0.12 rad. Consequently, the focus intensity and quality can be improved by introducing a phase shift of 0.12 rad for the tested transducer element.


In certain embodiments, mapping of the full transducer array is accomplished by varying and adjusting the phase (and/or amplitude) of each element, one at a time, while driving the remaining elements at constant phase. Typically, after each element has been mapped independently, the focus quality has significantly improved. Since the necessary phase adjustments of the transducer elements are all interrelated, however, the focus may not yet be optimal after one iteration. Therefore, in some embodiments, the procedure may be repeated iteratively. With each iteration, the phase adjustments made to maximize the displacement in the focus will, generally, decrease. Thus, a termination condition may be defined by setting a threshold value for phase adjustments, below which further adjustments are deemed immaterial or not clinically necessary. The number of iterations required to reach the termination condition may depend on the order in which the transducer elements are mapped. A mathematical algorithm, for example a “greedy algorithm” as known to persons of skill in the art, may be used to select a mapping order that results in fast convergence of the phase settings. In certain alternative embodiments, the transducer elements may be grouped, and groups of elements may be mapped simultaneously.



FIG. 7 illustrates a representative method for mapping an ultrasound transducer array in accordance with various embodiments of the invention. The method involves, in a first step 700, providing a phantom, and installing the transducer array and phantom in an MRI apparatus. Further, an imaging sequence defining the duration and relative times of ultrasound pulses, RF pulses, and encoding gradients is chosen (step 701). The phases of the transducer elements are then set to a constant value (step 702), and the focus location is determined by identifying the position of the phantom's maximal displacement in the MR-ARFI image (step 703). An iterative phase-adjustment process is subsequently started by selecting one element (or one group of elements) for mapping (step 704). The selected element is driven at a variable phase (step 708), and for each phase setting, the transducer elements are collectively driven to generate an ultrasound focus in the phantom (710). Substantially simultaneously, or after a time interval overlapping with the generation of the ultrasound focus, the displacement of phantom material in the focus region is measured by MR-ARFI in accordance with the imaging sequence (step 712). Typically, this step is repeated until the variable phase of the selected transducer element has covered a range of phases spanning an interval of 2π. In step 714, the phase difference between the constant phase and the phase of the selected transducer element that maximizes the displacement is determined (step 712). If the phase difference is non-zero, the phase of the transducer element is adjusted by this difference (step 718). Steps 704 through 718 are then repeated until each transducer element has been mapped. If the phase adjustments made in step 718 fall below a pre-determined threshold value, or an alternative termination condition is satisfied, the mapping is complete. Otherwise, the mapping procedure for the array may be repeated, starting with the adjusted phase settings of the transducer elements.


The method described above may be varied in several ways. For example, the phase differences may first be determined for all the elements, without adjustments being made, and following this mapping procedure, all the phase adjustments may be made at once. In this case, an iterative phase adjustment is not needed because the reference phase, i.e., the phase of the transducer as a whole, disregarding the element under mapping, is nearly the same for all elements. Further, in some embodiments, the phases of the transducer elements may be adjusted simultaneously, rather than in succession, by varying a drive parameter affecting some or all of the elements. For example, the relative phases between transducer elements may be expressed in terms of a functional dependence of the phase on the position of a transducer element along one or two axes of the transducer array, and such functional dependence, in turn, may be characterized by one or few mathematical parameters (e.g., a linear phase gradient and/or coefficients of higher-order components of the phase modulation in one- or two-dimensional space). Rather than modulating the phase of an individual element, then, the coefficients in the functional dependence may be varied, and the corresponding effect on the focus quality observed.


Alternatively or in addition to phase variations, amplitude variations of individual elements or groups of elements (including variations of the functional dependence of the amplitude on a position along the array) may also be employed to improve the focus quality. Further, in some embodiments, the transducer elements may be movable with respect to the one another within certain ranges (e.g., as a consequence of being mounted on electronically controllable microtranslator stages, pivots, etc.). The experimental adjustment procedure described above may then be used to fine-tune the positions and/or orientations of the transducer elements. The overall shape, position, and orientation of the transducer may likewise be controllable, e.g., via clasps, movable bearings, etc.


Although the present invention has been described with reference to specific details, it is not intended that such details should be regarded as limitations upon the scope of the invention, except as and to the extent that they are included in the accompanying claims.

Claims
  • 1. A method for mapping an ultrasound transducer comprising a plurality of transducer elements so as to improve a focus thereof, the method comprising: (a) driving the plurality of transducer elements so as to generate an ultrasound focus;(b) varying a phase associated with a selected one of the transducer elements while driving the other transducer elements at a constant phase and measuring a resulting variation on a displacement associated with the focus using magnetic-resonance (MR) acoustic radiation force imaging; and(c) selecting a value of the varied phase that is associated with a best focus quality by determining a phase difference, if any, between the constant and varied phases where the displacement is maximized and, if the phase difference is non-zero, adjusting a relative phase of the selected transducer element based thereon.
  • 2. The method of claim 1 further comprising scanning a profile of the focus.
  • 3. The method of claim 1 further comprising measuring a size of a cross-section of the focus.
  • 4. The method of claim 1 further comprising measuring an integral intensity of the focus.
  • 5. The method of claim 1 further comprising measuring a peak intensity of the focus.
  • 6. The method of claim 1 wherein the acoustic radiation force imaging comprises applying a sequence of MR field gradients.
  • 7. The method of claim 6 wherein the sequence of MR field gradients comprises repeated bipolar gradients.
  • 8. The method of claim 6 wherein step (a) comprises generating an ultrasound pulse synchronized with the sequence of MR field gradients.
  • 9. The method of claim 1 further comprising repeating steps (b) and (c) for the remaining transducer elements.
  • 10. The method of claim 1 further comprising the step of providing a phantom, the driving step generating an ultrasound focus in the phantom and the measuring step measuring a focus quality in the phantom.
  • 11. The method of claim 10 wherein the phantom comprises a material having low tensile strength.
  • 12. The method of claim 11 wherein the phantom comprises a material having a small elastic modulus.
  • 13. A method for controlling an ultrasound transducer comprising a plurality of transducer elements, the method comprising: (a) mapping the ultrasound transducer by (i) driving the plurality of transducer elements so as to generate an ultrasound focus in a phantom, (ii) varying a focus-affecting parameter associated with at least one of the elements and measuring a resulting variation on a quality of the focus using magnetic-resonance acoustic radiation force imaging, and (iii) selecting a value of the parameter associated with a best focus quality; and(b) controlling the transducer based on the mapping step so as to focus ultrasound into internal body tissue.
  • 14. The method of claim 13 wherein controlling the transducer comprises driving the elements to produce outputs converging at a focus corresponding to a target treatment region.
  • 15. The method of claim 13 further comprising, following step (b), repeating the mapping step.
  • 16. The method of claim 13 wherein substep (ii) comprises, for each of the transducer elements, determining a relative phase associated with the transducer element by (1) driving the transducer element at a variable phase while driving the other transducer elements at a constant phase, thereby varying the focus quality, and (2) determining a phase difference, if any, between the constant and variable phases where the focus quality is optimized.
  • 17. The method of claim 13, wherein the focus quality is measured using acoustic radiation force imaging to measure a displacement associated with the focus.
CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority to and the benefit of U.S. Provisional Patent Application No. 61/251,450, filed on Oct. 14, 2009, the entire disclosure of which is hereby incorporated herein by reference.

US Referenced Citations (257)
Number Name Date Kind
2795709 Camp Jun 1957 A
3142035 Harris Jul 1964 A
3559159 Harms Jan 1971 A
3942150 Booth et al. Mar 1976 A
3974475 Burckhardt et al. Aug 1976 A
3992693 Martin et al. Nov 1976 A
4000493 Spaulding et al. Dec 1976 A
4074564 Anderson Feb 1978 A
4206653 Lemay Jun 1980 A
4211132 Nichols, III et al. Jul 1980 A
4339952 Foster Jul 1982 A
4454597 Sullivan Jun 1984 A
4478083 Hassler et al. Oct 1984 A
4505156 Questo Mar 1985 A
4526168 Hassler et al. Jul 1985 A
4537074 Dietz Aug 1985 A
4549533 Cain et al. Oct 1985 A
4554925 Young Nov 1985 A
4662222 Johnson May 1987 A
4817614 Hassler et al. Apr 1989 A
4858597 Kurtze et al. Aug 1989 A
4865042 Umemura et al. Sep 1989 A
4888746 Wurster et al. Dec 1989 A
4889122 Watmough et al. Dec 1989 A
4893284 Magrane Jan 1990 A
4893624 Lele Jan 1990 A
4937767 Reuschel et al. Jun 1990 A
5197475 Antich et al. Mar 1993 A
5209221 Riedlinger May 1993 A
5211160 Talish et al. May 1993 A
5247935 Cline et al. Sep 1993 A
5271400 Dumoulin et al. Dec 1993 A
5275165 Ettinger et al. Jan 1994 A
5291890 Cline et al. Mar 1994 A
5307812 Hardy et al. May 1994 A
5307816 Hashimoto et al. May 1994 A
5318025 Dumoulin et al. Jun 1994 A
5323779 Hardy et al. Jun 1994 A
5327884 Hardy et al. Jul 1994 A
5329930 Thomas, III et al. Jul 1994 A
5368031 Cline et al. Nov 1994 A
5368032 Cline et al. Nov 1994 A
5379642 Reckwerdt et al. Jan 1995 A
5391140 Schaetzle et al. Feb 1995 A
5413550 Castel May 1995 A
5435312 Spivey et al. Jul 1995 A
5443068 Cline et al. Aug 1995 A
5474071 Chapelon et al. Dec 1995 A
5485839 Aida et al. Jan 1996 A
5490840 Uzgiris et al. Feb 1996 A
5507790 Weiss Apr 1996 A
5520188 Hennige et al. May 1996 A
5520612 Winder et al. May 1996 A
5526814 Cline et al. Jun 1996 A
5549638 Burdette Aug 1996 A
5553618 Suzuki et al. Sep 1996 A
5573497 Chapelon Nov 1996 A
5582578 Zhong et al. Dec 1996 A
5590653 Aida et al. Jan 1997 A
5590657 Cain et al. Jan 1997 A
5601526 Chapelon et al. Feb 1997 A
5605154 Ries et al. Feb 1997 A
5606971 Sarvazyan Mar 1997 A
5617371 Williams Apr 1997 A
5617857 Chader et al. Apr 1997 A
5643179 Fujimoto Jul 1997 A
5662170 Donovan et al. Sep 1997 A
5665054 Dory Sep 1997 A
5666954 Chapelon et al. Sep 1997 A
5676673 Ferre et al. Oct 1997 A
5687729 Schaetzle Nov 1997 A
5694936 Fujimoto et al. Dec 1997 A
5711300 Schneider et al. Jan 1998 A
5722411 Suzuki et al. Mar 1998 A
5728062 Brisken Mar 1998 A
5739625 Falcus Apr 1998 A
5743863 Chapelon Apr 1998 A
5752515 Jolesz et al. May 1998 A
5759162 Oppelt et al. Jun 1998 A
5762616 Talish Jun 1998 A
5769790 Watkins et al. Jun 1998 A
5810008 Dekel et al. Sep 1998 A
5810731 Sarvazyan et al. Sep 1998 A
5873845 Cline et al. Feb 1999 A
5891040 Grenon et al. Apr 1999 A
5897495 Aida et al. Apr 1999 A
5904659 Duarte et al. May 1999 A
5938600 Van Vaals et al. Aug 1999 A
5938608 Bieger et al. Aug 1999 A
5947900 Derbyshire et al. Sep 1999 A
5984881 Ishibashi et al. Nov 1999 A
6004269 Crowley et al. Dec 1999 A
6023636 Wendt et al. Feb 2000 A
6042556 Beach et al. Mar 2000 A
6071239 Cribbs et al. Jun 2000 A
6088295 Altes Jul 2000 A
6113559 Klopotek Sep 2000 A
6128522 Acker et al. Oct 2000 A
6128958 Cain Oct 2000 A
6135960 Holmberg Oct 2000 A
6193659 Ramamurthy et al. Feb 2001 B1
6217530 Martin et al. Apr 2001 B1
6242915 Hurd Jun 2001 B1
6263230 Haynor et al. Jul 2001 B1
6267734 Ishibashi et al. Jul 2001 B1
6289233 Dumoulin et al. Sep 2001 B1
6309355 Cain et al. Oct 2001 B1
6317619 Boernert et al. Nov 2001 B1
6322527 Talish Nov 2001 B1
6334846 Ishibashi et al. Jan 2002 B1
6374132 Acker et al. Apr 2002 B1
6392330 Zloter et al. May 2002 B1
6397094 Ludeke et al. May 2002 B1
6413216 Cain et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6424597 Bolomey et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6428532 Doukas et al. Aug 2002 B1
6433464 Jones Aug 2002 B2
6461314 Pant et al. Oct 2002 B1
6475150 Haddad Nov 2002 B2
6478739 Hong Nov 2002 B1
6506154 Ezion et al. Jan 2003 B1
6506171 Vitek et al. Jan 2003 B1
6511428 Azuma et al. Jan 2003 B1
6522142 Freundlich Feb 2003 B1
6523272 Morales Feb 2003 B1
6524251 Rabiner et al. Feb 2003 B2
6559644 Froundlich et al. May 2003 B2
6566878 Komura et al. May 2003 B1
6582381 Yehezkeli et al. Jun 2003 B1
6599256 Acker et al. Jul 2003 B1
6612988 Maor et al. Sep 2003 B2
6613004 Vitek et al. Sep 2003 B1
6613005 Friedman et al. Sep 2003 B1
6618608 Watkins et al. Sep 2003 B1
6618620 Freundlich et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6629929 Jago et al. Oct 2003 B1
6645162 Friedman et al. Nov 2003 B2
6652461 Levkovitz Nov 2003 B1
6666833 Friedman et al. Dec 2003 B1
6676601 Lacoste et al. Jan 2004 B1
6676602 Barnes et al. Jan 2004 B1
6679855 Horn et al. Jan 2004 B2
6705994 Vortman et al. Mar 2004 B2
6719694 Weng et al. Apr 2004 B2
6733450 Alexandrov et al. May 2004 B1
6735461 Vitek et al. May 2004 B2
6761691 Tsuzuki Jul 2004 B2
6770031 Hynynen et al. Aug 2004 B2
6770039 Zhong et al. Aug 2004 B2
6788619 Calvert Sep 2004 B2
6790180 Vitek Sep 2004 B2
6805129 Pless et al. Oct 2004 B1
6824516 Batten et al. Nov 2004 B2
6951540 Ebbini et al. Oct 2005 B2
6961606 DeSilets et al. Nov 2005 B2
7001379 Behl et al. Feb 2006 B2
7077820 Kadziauskas et al. Jul 2006 B1
7094205 Marmarelis Aug 2006 B2
7128711 Medan et al. Oct 2006 B2
7155271 Halperin et al. Dec 2006 B2
7175596 Vitek et al. Feb 2007 B2
7175599 Hynynen et al. Feb 2007 B2
7264592 Shehada Sep 2007 B2
7264597 Cathignol Sep 2007 B2
7267650 Chow et al. Sep 2007 B2
7344509 Hynynen et al. Mar 2008 B2
7377900 Vitek et al. May 2008 B2
7429248 Winder et al. Sep 2008 B1
7452357 Vlegele et al. Nov 2008 B2
7505805 Kuroda Mar 2009 B2
7505808 Anderson et al. Mar 2009 B2
7507213 Schultheiss et al. Mar 2009 B2
7510536 Foley et al. Mar 2009 B2
7511501 Wexler Mar 2009 B2
7535794 Prus et al. May 2009 B2
7553284 Vaitekunas Jun 2009 B2
7603162 Danz et al. Oct 2009 B2
7611462 Vortman et al. Nov 2009 B2
7652410 Prus Jan 2010 B2
7699780 Vitek et al. Apr 2010 B2
7819805 Davies et al. Oct 2010 B2
20010031922 Weng et al. Oct 2001 A1
20020016557 Duarte et al. Feb 2002 A1
20020035779 Krieg et al. Mar 2002 A1
20020082589 Friedman et al. Jun 2002 A1
20020095087 Mourad et al. Jul 2002 A1
20020111552 Maor et al. Aug 2002 A1
20020161300 Hoff et al. Oct 2002 A1
20020188229 Ryaby Dec 2002 A1
20030004439 Pant et al. Jan 2003 A1
20030060820 Maguire et al. Mar 2003 A1
20030187371 Vortman et al. Oct 2003 A1
20040030251 Ebbini et al. Feb 2004 A1
20040059265 Candy et al. Mar 2004 A1
20040068186 Ishida et al. Apr 2004 A1
20040122316 Satoh Jun 2004 A1
20040122323 Vortman et al. Jun 2004 A1
20040143187 Biagi et al. Jul 2004 A1
20040210134 Hynynen et al. Oct 2004 A1
20040210135 Hynynen et al. Oct 2004 A1
20040236253 Vortman et al. Nov 2004 A1
20040267126 Takeuchi Dec 2004 A1
20050033201 Takahashi et al. Feb 2005 A1
20050096542 Weng et al. May 2005 A1
20050131301 Peszynski et al. Jun 2005 A1
20050154304 Robinson Jul 2005 A1
20050203444 Schonenberger et al. Sep 2005 A1
20050251046 Yamamoto et al. Nov 2005 A1
20060052661 Gannot et al. Mar 2006 A1
20060052701 Carter et al. Mar 2006 A1
20060052706 Hynynen et al. Mar 2006 A1
20060058678 Vitek et al. Mar 2006 A1
20060106300 Seppenwoolde et al. May 2006 A1
20060173385 Lidgren et al. Aug 2006 A1
20060184034 Haim et al. Aug 2006 A1
20060184069 Vaitekunas Aug 2006 A1
20060206105 Chopra et al. Sep 2006 A1
20060229594 Francischelli et al. Oct 2006 A1
20060235302 Grossman et al. Oct 2006 A1
20070016039 Vortman et al. Jan 2007 A1
20070055140 Kuroda Mar 2007 A1
20070066897 Sekins et al. Mar 2007 A1
20070073135 Lee et al. Mar 2007 A1
20070098232 Matula et al. May 2007 A1
20070167781 Vortman et al. Jul 2007 A1
20070197918 Vitek et al. Aug 2007 A1
20070219470 Talish et al. Sep 2007 A1
20070239062 Chopra et al. Oct 2007 A1
20070276237 Li Nov 2007 A1
20080027342 Rouw et al. Jan 2008 A1
20080031090 Prus et al. Feb 2008 A1
20080033278 Assif Feb 2008 A1
20080082026 Schmidt et al. Apr 2008 A1
20080103558 Wenzel et al. May 2008 A1
20080108900 Lee et al. May 2008 A1
20080125660 Yao et al. May 2008 A1
20080183077 Moreau-Gobard et al. Jul 2008 A1
20080228081 Becker et al. Sep 2008 A1
20080312562 Routh et al. Dec 2008 A1
20090088623 Vortman et al. Apr 2009 A1
20090093721 Katsuyama Apr 2009 A1
20090118619 Oshiki May 2009 A1
20100030076 Vortman et al. Feb 2010 A1
20100056962 Vortman et al. Mar 2010 A1
20100125193 Zadicario May 2010 A1
20100179425 Zadicario Jul 2010 A1
20100268088 Prus et al. Oct 2010 A1
20100318002 Prus et al. Dec 2010 A1
20110066032 Vitek et al. Mar 2011 A1
20110130663 Raju et al. Jun 2011 A1
20110270136 Vitek et al. Nov 2011 A1
20120083695 Napolitano et al. Apr 2012 A1
20130077441 Ramamurthy et al. Mar 2013 A1
Foreign Referenced Citations (57)
Number Date Country
4345308 Feb 2001 DE
0151073 Aug 1985 EP
0320303 Jun 1989 EP
450334 Oct 1991 EP
467690 Jan 1992 EP
0558029 Sep 1993 EP
1132054 Sep 2001 EP
1774920 Apr 2007 EP
1790384 May 2007 EP
1936404 Jun 2008 EP
2806611 Sep 2001 FR
5-92008 Apr 1993 JP
07184907 Jul 1995 JP
7-231895 Sep 1995 JP
7-313518 Dec 1995 JP
11313833 Nov 1999 JP
00166940 Jun 2000 JP
01516075 Sep 2001 JP
02530145 Sep 2002 JP
WO-9100059 Jan 1991 WO
WO 9315415 Aug 1993 WO
WO-9514505 Jun 1995 WO
WO 9717018 May 1997 WO
WO-9852465 Nov 1998 WO
WO-0031614 Jun 2000 WO
WO-0159337 Aug 2001 WO
WO-0166189 Sep 2001 WO
WO-0180709 Nov 2001 WO
WO-0243805 Jun 2002 WO
WO-0244753 Jun 2002 WO
WO-02058791 Aug 2002 WO
WO-03013654 Feb 2003 WO
WO-03097162 Nov 2003 WO
WO-03098232 Nov 2003 WO
WO 2004021044 Mar 2004 WO
WO-2004093686 Nov 2004 WO
WO-2005038745 Apr 2005 WO
WO-2006018837 Feb 2006 WO
WO-2006025001 Mar 2006 WO
WO-2006087649 Aug 2006 WO
WO-2006119572 Nov 2006 WO
WO-2007051066 May 2007 WO
WO-2007073551 Jun 2007 WO
WO-2008039449 Apr 2008 WO
WO-2008050278 May 2008 WO
WO-2008075203 Jun 2008 WO
WO-2008119054 Oct 2008 WO
WO-2009055587 Apr 2009 WO
WO-2009081339 Jul 2009 WO
WO-2009094554 Jul 2009 WO
WO 2009085466 Jul 2009 WO
WO-2010058292 May 2010 WO
WO-2010082135 Jul 2010 WO
WO-2010119340 Oct 2010 WO
WO-2010143072 Dec 2010 WO
WO-2011013001 Feb 2011 WO
WO-2011024074 Mar 2011 WO
Non-Patent Literature Citations (42)
Entry
International Preliminary Report on Patentability for PCT/IB2010/002757 dated Apr. 17, 2012.
Nathan McDannold et al., Magnetic resonance acoustic radiation force imaging, Jul. 2008, Med. Phys., vol. 35, No. 8, pp. 3748-3758.
Botros et al., “A hybrid computational model for ultrasound phased-array heating in presence of strongly scattering obstacles,” IEEE Trans. on Biomed. Eng., vol. 44, No. 11, pp. 1039-1050 (Nov. 1997).
Cain et al., “Concentric-ring and Sector-vortex Phased-array Applicators for Ultrasound Hperthermia,” IEEE Trans. on Microwave Theory & Techniques, vol. MTT-34, No. 5, pp. 542-551 (May 1986).
Chen et al., “MR Acoustic Radiation Force Imaging: Comparison of Encoding Gradients.” 1 page, by Mar. 2007.
Cline et al., “Focused US system for MR imaging-guide tumor ablation,” Radiology, v. 194, No. 3, (Mar. 1995), pp. 731-737.
Cline et al., “MR Temperature mapping of focused ultrasound surgery,” Magnetic Resonance in Medicine, vol. 32, No. 6, pp. 628-636 (1994).
Cline et al., “Simultaneous magnetic resonance phase and magnitude temperature maps in muscle,” Magnetic Resonance in Medicine, vol. 35, No. 3, pp. 309-315 (Mar. 1996).
Daum et al., “Design and evaluation of a feedback based phased array system for ultrasound surgery,” IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 45, No. 2, pp. 431-434 (1998), in March.
de Senneville et al., “Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focussed Ultrasound,” Magnetic Resonance in Medicine 57:319-330 (2007).
Fjield et al, “The Combined Concentric-ring and Sector-vortex Phased Array for MRI Guided Ultrasound Surgery,” IEEE Trans. on Ultrasonics, Ferroelectrics and Freq. Cont., vol. 44, No. 5, pp. 1157-1167 (Sep. 1997).
Herbert et al., “Energy-based adaptive focusing of waves: application to ultrasonic transcranial therapy,” 8th Intl. Symp. on Therapeutic Ultrasound, Sep. 2009, 3 pages.
Huber et al., “A New Noninvasive Approach in Breast Cancer Therapy Using Magnetic Resonance Imaging-Guided Focussed Ultrasound Surgery,” Cancer Research 61, 8441-8447 (Dec. 2001).
Jolesz et al., “Integration of interventional MRI with computer-assisted surgery,” J. Magnetic Resonance Imaging. 12:69-77 (2001).
Kohler et al., “Volumetric HIFU Ablation guided by multiplane MRI thermometry,” 8th Intl. Symp. on Therapeutic Ultrasound, edited by E.S. Ebbini, U. of Minn. (Sep. 2009), pp. 228-230.
Kowalski et al., “Optimization of electromagnetic phased-arrays for hyperthermia via magnetic resonance temperature estimation,” IEEE Trans. on Biomed. Eng., vol. 49, No. 11, pp. 1229-1241 (Nov. 2002).
Maxwell et al., “Noninvasive thrombolysis using pulsed ultrasound cavitation therapy—Histotripsy,” Abstract, U.S. Natl. Lib. Of Med., NIH, Ultrasound Med. Biol. (Oct. 23, 2009).
McDannold et al., “MRI evaluation of thermal ablation of tumors and focused ultrasounds,” JMRI vol. 8, No. 1, pp. 91-100 (1998).
McDannold et al., “Magnetic resonance acoustic radiation force imaging,” Med. Phys. vol. 35, No. 8, pp. 3748-3758 (Aug. 2008).
Medel et al., “Sonothrombolysis: An emerging modality for the management of stroke,” Neurosurgery, vol. 65, No. 5, pp. 979-993, Nov. 2009.
Mougenot et al., “MR monitoring of the near-field HIFU heating,” 8th Intl. Symp. on Therapeutic Ultrasound, edited by E.S. Ebbini, U. of Minn. (Sep. 2009), pp. 159-161.
Vimeux et al., “Real-time control of focused ultrasound heating based on rapid MT thermometry,” Investig. Radiology, vol. 43, No. 3, pp. 190-193, 1999.
Vykhodtseva et al., “MRI detection of the thermal effects of focused ultrasound on the brain,” Ultrasound in Med. & Biol., vol. 26, No. 5, pp. 871-880 (2000).
“How is Ablatherm treatment performed?” http://www.edap-hifu.com/eng/physicians/hifu/3c—treatment—treat-description.htm, accessed Jan. 3, 2003,k 3 pages.
“What is HIFU? HIFU: High Intensity Focused Ultrasound,” http://www.edap-hifu.com/eng/physicians/hifu2a—hifu—overview.htm, accessed Jan. 3, 2003, 1 page.
“About HIFU What are the physical principles?” http://www.edap-hifu.com/eng/physicians/hifu/2c—hifu—physical.htm, accessed Jan. 3, 2003, 2 pages.
“How does HIFU create a lesion?” http://www.edap-hifu.com/eng/physicians/hifu/2d—hifu—lesion.htm, accessed Jan. 3, 2003, 1 page.
“Prostate Cancer Phase I Clinical Trials Using High Intensity Focused Ultrasound (HIFU),” Focus Surgery, http://www.focus-surgery.com/PCT%20Treatment%20with%20HIFU.htm, accessed Jan. 3, 2003, 2 pages.
“Abstract”. Focus Surgery, http://www.focus-surgery.com/Sanghvi.htm, accessed Jan. 3, 2003.
Exablate 2000 Specification, InSightec, Ltd. (2 pages), PUB 280002, by Mar. 2007.
FDA Approves Exablate 2000 as Non-invasive surgery for Fibroids, Oct. 22, 2004, 4 pages.
McGough et al., “Direct Computation of Ultrasound Phased-Array Driving Signals from a Specified Temperature Distribution for Hyperthermia,” IEEE TRansactions on Biomedical Engineering, vol. 39, No. 8, pp. 825-835 (Aug. 1992).
McDonnald et al. “Usefulness of MR Imaging-Derived Thermometry and Dosimetry in Determining the Threshold for Tissue Damage INduced by Thermal Surgery in Rabbits,” Radiology, vol. 216, No. 2000 pp. 517-523 (2000).
Suprijanto et al. “Displacement Correction Scheme for MR-Guided Interstitial Laser Therapy,” Ellis RE, Peters TM (Eds.): MiCCAI , LNCS 2879, pp. 399-407 (2003).
Shmatukha et al. “Correction of Proton Resonance Frequencey Shift Temperature Maps for Magnetic Field Disturbances Caused by Breathing,” Physics in Medicine and Biology, vol. 51, No. 18 pp. 4689-4705 (2006).
De Senneville et al., “An Optimised Multi-Baseline Approach for On-Line MR-Temperature Monitoring on Commodity Graphics Hardware,” Biomedical Imaging, pp. 1513-1516 (2008).
Vigen et al., “Triggered, Navigated, Multi-Baseline Method for Proton Resonance Frequency Temperature Mapping with Respiratory Motion,” Magnetic Resonance in Medicine, vol. 50, pp. 1003-1010 (2003).
Invitation to Pay Additional Fees and Partial Search Report mailed May 11, 2011 for International Application No. PCT/IB2010/002757 (5 pages).
Fronheiser et al., “3D Acoustic Radiation Force Impulse (ARFI) Imaging Using a 2D Matrix Array: Feasibility Study,” Ultrasonics Symposium, pp. 1144-1147 (Oct. 2006).
Wu et al., “MRImaging of Shear Waves Generated by Focused Ultrasound,” Magnetic Resonance in Medicine, vol. 43, pp. 111-115 (2000).
Heikkila et al., “Simulations of Lesion Detection Using a Combined Phased Array LHMI-Technique,” Ultrasonics, IPC Science and Technology Press Ltd., vol. 48, No. 6-7, pp. 568-573 (Nov. 2008).
International Search Report and Written Opinion mailed Sep. 7, 2011 for International Application No. PCT/IB2010/002757 ( 16 pages).
Related Publications (1)
Number Date Country
20110094288 A1 Apr 2011 US
Provisional Applications (1)
Number Date Country
61251450 Oct 2009 US